MAIA Biotech Insider Buying Surge: Guerrero Ramiro Adds 37,595 Shares, Signals Bullish Outlook for Immuno‑Oncology Pipeline and New Neuroprotective Programs
Guerrero Ramiro’s steady 9.8% stake growth in MAIA Biotechnology signals insider confidence in its immuno‑oncology pipeline and upcoming clinical data—a bullish cue for investors.
3 minutes to read